A new trading day began on Friday, with Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) stock price down -2.09% from the previous day of trading, before settling in for the closing price of $7.18. AUPH’s price has ranged from $4.71 to $10.05 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 3168.98% over the last five years. Meanwhile, its annual earnings per share averaged 108.95%. With a float of $128.68 million, this company’s outstanding shares have now reached $143.83 million.
The firm has a total of 300 workers. Let’s measure their productivity. In terms of profitability, gross margin is 86.08%, operating margin of -23.32%, and the pretax margin is -23.22%.
Aurinia Pharmaceuticals Inc (AUPH) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Aurinia Pharmaceuticals Inc is 10.01%, while institutional ownership is 40.36%. The most recent insider transaction that took place on Aug 06 ’24, was worth 96,902. In this transaction Chief Commercial Officer of this company sold 18,249 shares at a rate of $5.31, taking the stock ownership to the 456,338 shares. Before that another transaction happened on May 21 ’24, when Company’s Director sold 520 for $5.74, making the entire transaction worth $2,985. This insider now owns 17,523 shares in total.
Aurinia Pharmaceuticals Inc (AUPH) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 108.95% per share during the next fiscal year.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Trading Performance Indicators
Here are Aurinia Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit 0.01 in the next quarter and is forecasted to reach 0.42 in one year’s time.
Technical Analysis of Aurinia Pharmaceuticals Inc (AUPH)
Analysing the last 5-days average volume posted by the [Aurinia Pharmaceuticals Inc, AUPH], we can find that recorded value of 0.76 million was lower than the volume posted last year of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 71.53%. Additionally, its Average True Range was 0.24.
During the past 100 days, Aurinia Pharmaceuticals Inc’s (AUPH) raw stochastic average was set at 82.23%, which indicates a significant increase from 55.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.10% in the past 14 days, which was lower than the 43.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.78, while its 200-day Moving Average is $6.12. Now, the first resistance to watch is $7.19. This is followed by the second major resistance level at $7.34. The third major resistance level sits at $7.46. If the price goes on to break the first support level at $6.91, it is likely to go to the next support level at $6.79. Should the price break the second support level, the third support level stands at $6.64.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Key Stats
With a market capitalization of 1.01 billion, the company has a total of 142,664K Shares Outstanding. Currently, annual sales are 175,510 K while annual income is -78,020 K. The company’s previous quarter sales were 57,190 K while its latest quarter income was 720 K.
